|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
ATE423120T1
(de)
*
|
2000-06-26 |
2009-03-15 |
Pfizer Prod Inc |
Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
ATE402700T1
(de)
*
|
2002-08-27 |
2008-08-15 |
Merck Patent Gmbh |
Glycinamid-derivate als raf-kinase-hemmer
|
|
NZ539901A
(en)
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
AU2005237254B2
(en)
*
|
2004-05-03 |
2010-02-04 |
Novartis Ag |
Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
|
|
MXPA06015237A
(es)
|
2004-06-29 |
2007-12-10 |
Amgen Inc |
Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
|
|
JP2008508358A
(ja)
|
2004-08-02 |
2008-03-21 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
|
|
AU2005309019A1
(en)
*
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
WO2007007919A2
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
EP1913000B1
(en)
*
|
2005-07-29 |
2012-01-11 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
|
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
NZ582188A
(en)
*
|
2007-07-11 |
2012-03-30 |
Pfizer |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
JP2011529918A
(ja)
*
|
2008-08-01 |
2011-12-15 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ３阻害剤としてのピペリジン誘導体
|
|
KR101335843B1
(ko)
|
2008-08-20 |
2013-12-02 |
조에티스 엘엘씨 |
피롤로[2,3-ｄ]피리미딘 화합물
|
|
WO2010093808A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
AU2010239396B2
(en)
|
2009-04-20 |
2016-06-23 |
Auspex Pharmaceuticals, Llc |
Piperidine inhibitors of Janus Kinase 3
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
SI2432472T1
(sl)
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
JP5658756B2
(ja)
*
|
2009-09-10 |
2015-01-28 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｊａｋの阻害剤
|
|
EA021478B1
(ru)
|
2009-10-09 |
2015-06-30 |
Инсайт Корпорейшн |
ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
|
|
ES2426407T3
(es)
|
2009-10-15 |
2013-10-23 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
WO2011075334A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
RU2012132278A
(ru)
*
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
|
MX2012009074A
(es)
|
2010-02-05 |
2012-08-23 |
Pfizer |
Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
EP2481411A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
|
|
EP2481397A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising tasocitinib
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
EP2691395B1
(en)
|
2011-03-28 |
2017-08-30 |
ratiopharm GmbH |
Processes for preparing tofacitinib salts
|
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
|
RU2013144975A
(ru)
|
2011-04-08 |
2015-05-20 |
Пфайзер Инк. |
Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
|
|
ES2414384T3
(es)
|
2011-05-11 |
2013-07-19 |
Ratiopharm Gmbh |
Composición de liberación modificada que comprende ranolazina
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
ES3018133T3
(en)
|
2011-11-30 |
2025-05-14 |
Univ Emory |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
US10821111B2
(en)
|
2011-11-30 |
2020-11-03 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
EP3170827A1
(en)
|
2011-12-15 |
2017-05-24 |
ratiopharm GmbH |
Tofacitinib mono-oxalate salt
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
WO2014016338A1
(en)
|
2012-07-25 |
2014-01-30 |
Lek Pharmaceuticals D.D. |
New synthetic route for the preparation of 3-amino-piperidine compounds
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
WO2014083150A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Lek Pharmaceuticals D.D. |
Preparation of 3-amino-piperidine compounds via nitro-tetrahydropyridine precursors
|
|
WO2014097150A1
(en)
|
2012-12-17 |
2014-06-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of tofacitinib and intermediates thereof
|
|
EP2938616A4
(en)
|
2012-12-28 |
2016-06-15 |
Glenmark Pharmaceuticals Ltd |
PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
|
|
GEP201606600B
(en)
|
2013-02-22 |
2017-01-10 |
Pfizer |
Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
|
US20140343034A1
(en)
|
2013-04-25 |
2014-11-20 |
Japan Tobacco Inc. |
Skin barrier function improving agent
|
|
WO2014174073A1
(en)
|
2013-04-26 |
2014-10-30 |
Sandoz Ag |
Sustained release formulations of tofacitinib
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
CN104513248B
(zh)
*
|
2013-09-30 |
2019-05-24 |
重庆医药工业研究院有限责任公司 |
一种托法替尼中间体的纯化方法
|
|
SI3077395T1
(en)
|
2013-12-05 |
2018-03-30 |
Pfizer Inc. |
Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
|
|
BR112015025543B1
(pt)
|
2013-12-09 |
2020-11-03 |
Unichem Laboratories Limited |
processo para a preparação de (3r,4r)-(1-benzil-4- metilpiperidina-3-il)-metilamina e compostos intermediários
|
|
CA2881262A1
(en)
|
2014-02-06 |
2015-08-06 |
Prabhudas Bodhuri |
Solid forms of tofacitinib salts
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
EA036122B1
(ru)
*
|
2015-01-20 |
2020-09-30 |
Уси Форчун Фармасьютикал Ко., Лтд |
Ингибитор jak
|
|
JP6687596B2
(ja)
*
|
2015-02-17 |
2020-04-22 |
アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法
|
|
CN104761556B
(zh)
*
|
2015-03-21 |
2017-06-23 |
河北国龙制药有限公司 |
托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
|
|
EP3078665A1
(en)
|
2015-04-10 |
2016-10-12 |
OLON S.p.A. |
Efficient method for the preparation of tofacitinib citrate
|
|
AU2016254385B2
(en)
|
2015-04-29 |
2018-05-10 |
Wuxi Fortune Pharmaceutical Co., Ltd |
JAK inhibitors
|
|
EP3288943B1
(en)
|
2015-05-01 |
2022-09-28 |
Pfizer Inc. |
Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
|
|
KR102081272B1
(ko)
|
2015-05-29 |
2020-02-25 |
우시 포춘 파마슈티컬 컴퍼니 리미티드 |
Janus 키나아제 억제제
|
|
KR101964546B1
(ko)
*
|
2015-07-27 |
2019-04-01 |
유니켐 레버러토리스 리미티드 |
토파시티닙 경구 붕해 정제
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
CN105348287A
(zh)
*
|
2015-11-30 |
2016-02-24 |
宁波立华制药有限公司 |
一种枸橼酸托法替布的新型合成工艺
|
|
KR102565407B1
(ko)
*
|
2016-01-04 |
2023-08-10 |
(주)아모레퍼시픽 |
극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
|
|
WO2017125417A1
(en)
|
2016-01-18 |
2017-07-27 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Tofacitinib as vaccination immune modulator
|
|
MX388591B
(es)
|
2016-06-30 |
2025-03-20 |
Daewoong Pharmaceutical Co Ltd |
Derivados de pirazolopirimidina como inhibidor de cinasa.
|
|
CN106831538B
(zh)
*
|
2017-01-22 |
2019-06-25 |
苏州楚凯药业有限公司 |
托法替尼中间体的制备方法
|
|
KR102398659B1
(ko)
|
2017-03-17 |
2022-05-16 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 피롤로트리아진 유도체
|
|
CN107602569A
(zh)
*
|
2017-10-23 |
2018-01-19 |
上海博悦生物科技有限公司 |
一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
|
|
KR102078805B1
(ko)
|
2017-11-30 |
2020-02-19 |
보령제약 주식회사 |
토파시티닙을 포함하는 약제학적 조성물
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
RU2758370C1
(ru)
|
2017-12-28 |
2021-10-28 |
Даевунг Фармасьютикал Ко., Лтд. |
Производные оксифторпиперидина в качестве ингибитора киназы
|
|
KR102577241B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
|
|
KR102577242B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
|
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
US12161748B2
(en)
|
2018-01-31 |
2024-12-10 |
Twi Biotechnology, Inc. |
Topical formulations comprising tofacitinib
|
|
SG11202006782YA
(en)
*
|
2018-01-31 |
2020-08-28 |
Twi Pharmaceuticals Inc |
Topical formulations comprising tofacitinib
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
KR102131107B1
(ko)
*
|
2019-01-15 |
2020-07-07 |
주식회사 다산제약 |
3-아미노-피페리딘 화합물의 신규한 제조 방법
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
US12364696B2
(en)
|
2019-02-27 |
2025-07-22 |
Jak Slave Pty Ltd |
Treatment of autoimmune disease
|
|
WO2020183295A1
(en)
|
2019-03-13 |
2020-09-17 |
Intas Pharmaceuticals Ltd. |
Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
|
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
|
WO2020204647A1
(en)
|
2019-04-05 |
2020-10-08 |
Yuhan Corporation |
Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
|
|
US20220401447A1
(en)
|
2019-11-08 |
2022-12-22 |
Cage Bio, Inc. |
Topical delivery of tofacitinib using ionic liquid
|
|
US20220378707A1
(en)
|
2019-11-14 |
2022-12-01 |
Pfizer Inc. |
1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
|
|
KR102877132B1
(ko)
*
|
2019-11-25 |
2025-10-27 |
주식회사 대웅제약 |
신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
|
|
IL297050A
(en)
|
2020-04-04 |
2022-12-01 |
Pfizer |
Methods of treating the 2019 corona virus disease
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022194782A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Chiesi Farmaceutici S.P.A. |
Heterocyclic derivatives as janus kinase inhibitors
|
|
CN113549075B
(zh)
*
|
2021-06-23 |
2025-09-23 |
合肥华方医药科技有限公司 |
一种枸橼酸托法替布非对映异构体杂质的合成方法
|
|
EP4180042A1
(en)
|
2021-11-15 |
2023-05-17 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising micronized tofacitinib
|